Novel neuropeptides in the pathophysiology of heart failure: adrenomedullin and endothelin‐1
暂无分享,去创建一个
[1] A. Protter,et al. Pharmacokinetics and biological actions of subcutaneously administered human brain natriuretic peptide. , 1998, The Journal of pharmacology and experimental therapeutics.
[2] Omapatrilat, a novel cardiovascular agent, improves hemodynamics in patients with heart failure , 1998 .
[3] J. Cleland,et al. Short-term haemodynamic effects of BQ-123, a selective endothelin ETA-receptor antagonist, in chronic heart failure , 1998, The Lancet.
[4] K. Swedberg,et al. Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure , 1998, The Lancet.
[5] D. Webb,et al. Nitric Oxide Synthesis and by Endothelin-B Receptor Blockade Mediated Vasodilatation Is Attenuated by Inhibition of − Endothelin-A Receptor Antagonist , 1998 .
[6] W. Abraham,et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. , 1998, Journal of cardiac failure.
[7] M. Packer,et al. MULTICENTER, DOUBLEBLIND PLACEBO CONTROLLED STUDY OF LONG TERMENDOTHELIN BLOCKADE WITH BOSENTAN IN CHRONIC HEART FAILURE RESULTS OF THE REACH-1 TRIAL. ABSTRACT , 1998 .
[8] A. Richards,et al. Infusion or co-infusion of brain natriuretic peptide and/or adrenomedullin in human heart failure , 1998 .
[9] G. Cooper,et al. Beneficial hemodynamic and renal effects of adrenomedullin in an ovine model of heart failure. , 1997, Circulation.
[10] S. Barker,et al. Adrenomedullin acts as a local mediator of vascular homeostasis through interactions which lead to reduced endothelin-1 synthesis and secretion , 1997, Journal of Human Hypertension.
[11] L. Malendowicz,et al. Effects of adrenomedullin on the human adrenal glands: an in vitro study. , 1997, The Journal of clinical endocrinology and metabolism.
[12] N. Arakawa,et al. Potent and long-lasting vasodilatory effects of adrenomedullin in humans. Comparisons between normal subjects and patients with chronic heart failure. , 1997, Circulation.
[13] B. Cheung,et al. Elevated plasma levels of human adrenomedullin in cardiovascular, respiratory, hepatic and renal disorders. , 1997, Clinical science.
[14] D. Heitjan,et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. , 1996, Circulation.
[15] K. Buchanan,et al. Adrenomedullin: a novel cardiovascular regulatory peptide. , 1996, QJM : monthly journal of the Association of Physicians.
[16] D. Webb,et al. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. , 1996, Circulation.
[17] L. Miller,et al. Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. , 1996, The American journal of cardiology.
[18] K. Kitamura,et al. Inhibition of aldosterone production by adrenomedullin, a hypotensive peptide, in the rat. , 1996, Hypertension.
[19] R. Rodeheffer,et al. Cardiac secretion of adrenomedullin in human heart failure. , 1996, The Journal of clinical investigation.
[20] D. Webb,et al. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. , 1996, Circulation.
[21] Y. Koiwaya,et al. Increased plasma adrenomedullin levels in chronic congestive heart failure. , 1996, American heart journal.
[22] A. Lerman,et al. Enhanced Coronary Vasoconstriction to Endothelin-BReceptor Activation in Experimental Congestive Heart Failure , 1996 .
[23] A. Lerman,et al. Enhanced coronary vasoconstriction to endothelin-B-receptor activation in experimental congestive heart failure. , 1996, Circulation.
[24] T. Ishimitsu,et al. Increased plasma levels of adrenomedullin in patients with heart failure. , 1995, Journal of the American College of Cardiology.
[25] M. Fujishima,et al. Cardiovascular and neurohormonal effects of intravenous adrenomedullin in conscious rabbits. , 1995, The American journal of physiology.
[26] P. Hunziker,et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure , 1995, The Lancet.
[27] O. Kida,et al. HAEMODYNAMIC RESPONSES TO RAT ADRENOMEDULLIN IN ANAESTHETIZED SPONTANEOUSLY HYPERTENSIVE RATS , 1995, Clinical and experimental pharmacology & physiology.
[28] J. Burnett,et al. Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. , 1995, Circulation.
[29] T. Horio,et al. Inhibition of endothelin production by adrenomedullin in vascular smooth muscle cells. , 1995, Hypertension.
[30] J. Cleland,et al. Renal response to candoxatrilat in patients with heart failure. , 1995, Journal of the American College of Cardiology.
[31] S. Gardiner,et al. Regional haemodynamic effects of human and rat adrenomedullin in conscious rats , 1995, British journal of pharmacology.
[32] T. Yamaguchi,et al. Effect of adrenomedullin on aldosterone secretion by dispersed rat adrenal zona glomerulosa cells. , 1994, Life sciences.
[33] P. Nihoyannopoulos,et al. Elevated plasma endothelin concentrations in heart failure; an effect of angiotensin II? , 1994, European heart journal.
[34] D. Webb,et al. Contribution of endogenous generation of endothelin-1 to basal vascular tone , 1994, The Lancet.
[35] N. Minamino,et al. Production and secretion of adrenomedullin from vascular smooth muscle cells: augmented production by tumor necrosis factor-alpha. , 1994, Biochemical and biophysical research communications.
[36] K. Miyamoto,et al. Endothelial cells actively synthesize and secrete adrenomedullin. , 1994, Biochemical and biophysical research communications.
[37] W. Summer,et al. Adrenomedullin dilates the pulmonary vascular bed in vivo. , 1994, Journal of applied physiology.
[38] W. Edwards,et al. Endothelin in human congestive heart failure. , 1994, Circulation.
[39] K. Kangawa,et al. Immunoreactive adrenomedullin in human plasma , 1994, FEBS letters.
[40] D. Kohan. Endothelins in the kidney: physiology and pathophysiology. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[41] K. Miyatake,et al. Rapid increase in plasma endothelin concentrations during percutaneous balloon dilatation of the mitral valve in patients with mitral stenosis. , 1993, British heart journal.
[42] G. Riegger,et al. Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure. , 1992, The American journal of cardiology.
[43] P. Binkley,et al. Plasma Endothelin Correlates With the Extent of Pulmonary Hypertension in Patients With Chronic Congestive Heart Failure , 1992, Circulation.
[44] F. Marumo,et al. Plasma endothelin-1 levels in idiopathic dilated cardiomyopathy. , 1991, The American journal of cardiology.
[45] H. Imura,et al. Hemodynamic, Renal, and Hormonal Responses to Brain Natriuretic Peptide Infusion in Patients With Congestive Heart Failure , 1991, Circulation.
[46] M. Shichiri,et al. Cellular Mechanism of Endothelin‐1 Release by Angiotensin and Vasopressin , 1991, Hypertension.
[47] A. Jardine,et al. Inhibition of the metabolism of atrial natriuretic factor causes diuresis and natriuresis in chronic heart failure. , 1990, American journal of hypertension.
[48] L. V. von Segesser,et al. Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries. A new mechanism of vasospasm? , 1990, Circulation.
[49] Sadao Kimura,et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells , 1988, Nature.
[50] J. Cohn,et al. The neurohumoral axis in congestive heart failure. , 1984, Annals of internal medicine.
[51] P. Harris. Evolution and the cardiac patient. , 1983, Cardiovascular research.